CSL (OTCMKTS:CSLLY) Sets New 1-Year Low on Analyst Downgrade

CSL Limited Sponsored ADR (OTCMKTS:CSLLY) shares hit a new 52-week low during mid-day trading on Thursday after Royal Bank Of Canada downgraded the stock from a moderate buy rating to a hold rating. The stock traded as low as $52.00 and last traded at $54.0950, with a volume of 6737 shares traded. The stock had previously closed at $56.82.

Several other analysts have also recently commented on CSLLY. Zacks Research upgraded CSL from a “strong sell” rating to a “hold” rating in a research report on Monday, December 29th. Canaccord Genuity Group raised shares of CSL from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 28th. One analyst has rated the stock with a Strong Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy”.

CSL Stock Down 4.8%

The firm’s fifty day simple moving average is $59.83 and its 200 day simple moving average is $65.65. The company has a quick ratio of 1.12, a current ratio of 2.46 and a debt-to-equity ratio of 0.50.

About CSL

CSL Limited (OTCMKTS: CSLLY) is a global biotechnology company headquartered in Melbourne, Australia that develops, manufactures and delivers a range of plasma-derived and recombinant therapeutics, vaccines and related services. Its principal businesses include CSL Behring, which focuses on specialty biotherapies for bleeding disorders, immune deficiencies, hereditary angioedema and other serious conditions; Seqirus, an influenza vaccine company formed following CSL’s acquisition of Novartis’ influenza vaccine business; and CSL Plasma, a network of plasma collection centers that supplies the raw material for many of its therapies.

The company’s product portfolio spans immunoglobulins, clotting factor concentrates, albumin and other protein-based treatments used in the management of chronic and acute rare diseases, as well as seasonal and pandemic influenza vaccines.